Physician profile
Jonathan R Maynard
NPI 1992970115
$1,522.22
in general payments reported to CMS, 2019-2025
11 companies · $136 in 2025
The $136 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.12 · 2020: $16.35 · 2021: $182 · 2022: $397 · 2023: $425 · 2024: $294 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $638.48 | 2021-2024 | Qelbree |
| Corium, LLC | $365.27 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $171.02 | 2021-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $136.99 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Collegium Pharmaceutical, INC. | $102.18 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.10 | 2019 | |
| Sobi, INC | $21.06 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $20.35 | 2022 | |
| Soleno Therapeutics, INC. | $17.71 | 2025 | Vykat Xr |
| Glaxosmithkline, LLC. | $15.00 | 2019 | |
| Pfizer INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.